PRTC News and Press, PureTech Health plc From 11/16/21

LYT-100 well-tolerated at all doses studied with a favorable PK profile; maximum tolerated dose not determined; additional studies underway to evaluate higher doses Phase 2 enrollment of LYT-100 in patients with Long COVID 1 respiratory complications expected to complete b...

Company to participate in fireside chats at Piper Sandler Healthcare Conference and Evercore ISI HealthCONx Conference PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedica...

LYT-200 is being advanced in a range of difficult-to-treat solid tumors including pancreatic cancer, colorectal cancer and cholangiocarcinoma Phase 1 portion of its adaptive Phase 1/2 trial with LYT-200 in solid tumors continues to progress, with a maximum tolerated dose n...

LYT-200 is being advanced in a range of difficult-to-treat solid tumors including pancreatic cancer, colorectal cancer and cholangiocarcinoma Phase 1 portion of its adaptive Phase 1/2 trial with LYT-200 in solid tumors continues to progress, with a maximum tolerated dose not y...

A monoclonal antibody under development from PureTech Health (PRTC) has been granted Orphan Drug status from the FDA for pancreatic cancer. The anti-galectin-9 candidate is in phase 1 of development. PureTech most advanced asset is LYT-100 (deupirfenidone), in phase 2 for long COVID respirato...

Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term development and commercial milestones and other payments, and low-double-digit to hig...

Company reports PureTech Level Cash and Cash Equivalents of $387.3 million 1 and Consolidated Cash and Cash Equivalents of $441.0 million 2 as of September 30, 2021 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company...

New paper in important scientific journal describes the first superabsorbent hydrogel technology made from naturally derived building blocks designed to address obesity and gut related conditions by emulating compositional and mechanical properties of raw vegetables The newly ...

High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defi...

Sonde extends use of its voice-based health detection and monitoring platform beyond respiratory illness to cognitive and mental health conditions PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stag...